All News

Once a recommended dose of the drug is determined, the study investigators will review the efficacy and safety associated with this treatment across a variety of patients with bladder and liver cancer, as well other solid tumors.

An expert discusses the side effects patients with kidney cancer may experience from immunotherapy and tyrosine kinase inhibitor treatment, and how more research is needed in to ensure patients experience less side effects.

There are so many things I wish I’d known before being diagnosed with breast cancer, but if I’d known them all in advance, I wouldn’t have learned many valuable lessons.

From Philadelphia Flyers’ employees suing the organization after developing a rare blood cancer to experts proposing a new name for low-risk prostate cancer and an actor on Disney+’s “The Mandolorian” dying of cancer, here’s what is happening in the cancer space this week.

Watch Dr. Jose Karam, from The University of Texas MD Anderson Cancer Center, discuss surgical options, during the CURE Educated Patient Kidney Cancer Summit.

The pharmaceutical company developing a combination regimen of ublituximab plus Ukoniq (known as U2) pulled the drug duo’s indications for the treatment of multiple types of blood cancer after clinical trial results fell short of improving overall survival.

I can’t plan anything without planning time to rest. I literally have to schedule my whole day around when I can lie down to nap.

As the COVID-19 pandemic seems to be winding down, I’ll still be masking up, knowing that it could return as quickly as it left.

Experts from Cancer Treatment Centers of America explain why mental health is important from cancer diagnosis through survivorship, the types of therapy and more.

Findings from an early-phase clinical trial show that treatment with epcoritamab led to a 63.1% response rate in patients with pretreated large B-cell lymphoma.

An expert noted that despite the results, all patients with cancer should be aware of their increased risk for developing blood clots.

My wife and I took a weekend break from the worries of cancer and everyday life, but things did not go as planned, forcing me to tap into all the self-work I’ve been focusing on this year.

By understanding what a TNM staging score is, patients and clinicians can determine the best line of treatment for their kidney cancer, as well as what the survivorship care plan should be.

Watch Dr. Rana R. McKay, from the University of California San Diego, discuss genetic testing in renal cell carcinoma during the CURE Educated Patient Kidney Cancer Summit.

The clinical development of BEMPEG plus Opdivo will end after clinical trials showed that the drug combination did not lead to significant improvements in outcomes in patients with kidney or bladder cancer.

Patients with early-stage breast cancer are advised to ask their provider what the least invasive treatment option is available to them that gives them both a great cure rate and a much better quality of life.

After going public with my cancer diagnosis, I was met with an onslaught of “grief tourists” who may not have been interested in the harsh realities of cancer.

Patients within the study who developed the rare skin condition were more likely to experience better tumor responses than those who did not develop the side effect.

Watch Dr. Vitaly Margulis, from UT Southwestern Medical Center, discuss staging, during the CURE Educated Patient Kidney Cancer Summit.

Patients with myeloproliferative neoplasms, a group of blood cancers, who plan to conceive should talk with their doctor about their obstetric and medical history and risk of complications, according to an expert.

An expert discusses the resources and support available to people to better face their end-of-life journey.

A trauma therapist who specializes in cancer would have been helpful for my wife and I as we navigated her cancer experience, but the option was never discussed at our health care visits.

Activating mutations in this class of oncogenes, specifically KRAS, have made a big step forward scientifically and clinically just in the last couple of years.

The plan to launch the phase 1 trial to evaluate the safety and efficacy of combining the CAR-T cell therapy and oncolytic virus in patients with recurrent glioblastoma, a type of brain cancer, is supported by interim data from two ongoing trials.

Upon reflecting on my late wife's cancer experience, one of my major regrets is not properly saying goodbye.

Recent advancements surrounding the development of biomarker- targeted therapies have revolutionized the treatment of lung cancer.

The plan, according to the San Diego-based pharmaceutical company, is to launch a phase 3 trial to analyze the safety and efficacy of a novel drug in mantle cell lymphoma in the second half of 2022.

The primary focus of the trial is to evaluate the incidence of treatment-emergent and serious side effects in patients receiving either the novel drug alone or in combination with Keytruda.